Dina Ben‐Yehuda

机构：Hebrew University of Jerusalem

发表论文 204 篇 · 总被引 13015 次 · h-index 47

代表论文

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial (2018 · The Lancet Oncology · 被引 557)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial (2019 · The Lancet Oncology · 被引 390)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study (2019 · The Lancet Haematology · 被引 195)
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients (2017 · Blood · 被引 113)
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs (2019 · Haematologica · 被引 64)
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial (2022 · The Lancet Haematology · 被引 48)